Ranolazine, sold under the trade name Ranexa by Gilead Sciences (who acquired the developer, CV Therapeutics in 2009), is an antianginal medication. In India, it is sold under the name "Ranozex". On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina pectoris.
Read more about Ranolazine: Mechanism of Action, Indications For Use, Contraindications, Metabolism